

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lerner, Adam
Serial No.: To be assigned
Filed: Herewith
For: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

GROUP: Unassigned
EXAMINER: Unassigned



DIVISIONAL OF:

Applicants: LERNER, Adam
Serial No.: 09/423,349
Filed: November 22, 1999
For: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC
LYMPHOCYTIC LEUKEMIA

Group No.: 1614
Examiner: Goldberg, J.

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Express Mail Label No. EL565098651US service under 37 CFR 1.10, on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 1/30/02

Zinna L. Mang

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed in connection with a divisional application.

Lerner, Adam
U.S.S.N.: 09/423,349
Page 2

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):


 x Copy of references BC and BO are enclosed herewith; and
 x Other references have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



Ronald I. Eisenstein (Reg. 30,628)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6054

Date: 1/30/02

FORM PTO-1449		DOCKET NO.:		SERIAL NO.: To be assigned	
INFORMATION DISCLOSURE		701586/50176 DIV			
STATEMENT		APPLICANT(S): Adam Lerner			
		FILING DATE: Herewith		GROUP NO.: Unassigned	
U.S. PATENT DOCUMENTS					
	AA	5,529,914	Hubbell et al.	06/25/1996	
	AB	5,573,934	Hubbell et al.	11/12/1996	
	AC	5,601,844	Kagayama et al.	02/11/1997	
	AD	5,591,776	Cavalla et al.	01/07/1997	
	AE	5,622,977	Warrellow et al.	04/22/1997	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
	BA	DEVITA, V.T., ROSENBERG, S.A., HELLMAN, S., "Cancer: Principles & Practice of Oncology." 3rd ed., J. B. Lippincott Company, p. 1843-1847 (1989).			
	BB	DANIEL, V. ET AL., "Induction of cytolysis of cultured lymphoma cells by adenosine 3':5'-cyclic monophosphate and isolation of resistant variants. " Proc. Natl. Acad. Sci. USA, 70:76 (1973).			
	BC	MCCONCEY, D.J. ET AL., "Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. " J. Immunol., 145:1227 (1990).			
	BD	LOMO, J. ET AL., "TGB-b1 and cyclic AMP promote apoptosis in resting human B lymphocytes." J. Immunol., 154:1634 (1995).			
	BE	SCHWABE, U. ET AL., "4-(3-cyclopentyloxy-4-methoxyphenyl)-2pyrrilidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain." Molecular Pharmacology, 12:900 (1976).			
	BF	SHEPPARD, H. ET AL., "Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. " Adv. Cyclic Nucl. Res., 1:103 (1972).			
	BG	SILBER, R and STAHL, R., "Chronic lymphocytic leukemia and related diseases." In Hematology 4th ed., W.J. Williams et al. Eds., McGraw-Hill, Inc., p. 1005-1025 (1990).			
	BH	BROWN, B.A., "Hematology: Principles and Procedures." 3rd ed. Lea & Febiger, PA, p. 248-250 (1980).			
	BI	DALE, D.C. and FEDERMAN, D.D. "The leukemias and the myeloproliferative disorders." Scientific American Medicine 2:16-29 (1996).			
	BJ	MENTZ, F. et al. "Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides." British Journal of Haematology 90:957-959 (1995).			
	BK	MENTZ, F. et al. "Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells." Blood 88:2172-2182 (1996).			
	BL	ZURBONSEN K. et al. "Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the dami cell line." Biochemical Pharmacology 53:1141-1147 (1997).			
	BM	WEISS, B. and HAIT, W.N. "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents." Ann. Rev. Pharmacol. Toxicol. 17:441-477 (1977).			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		DOCKET NO.:	SERIAL NO.: To be assigned
		701586/50174-DIV	
		APPLICANT(S): Adam Lerner	
		FILING DATE: Herewith	GROUP NO.: Unassigned
	BN	DREES, M. et al. "3',5'-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition." Cancer Research 53:3058-3061 (1993).	
	BO	JIANG, X. et al. "Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells." Proc. Natl. Acad. Sci. USA 93:11236-11241 (1996).	
	BP	ZHU W-H. et al. "Cyclic AMP-specific phosphodiesterase inhibitor rolipam and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism." Life Sci. 63:265-74 (1998).	
		NON-PATENT DOCUMENTS	
	CA	Zhu et al., <i>Life Sci.</i> , 673(4), 265-274 (1998) Abstract Only	
	CB	Kim et al., <i>Blood</i> , 92(7), 2484-2494 (1998) Abstract Only	
EXAMINER:			DATE: